Kezar Life Sciences Inc (KZR)

Dec 21, 2024

Wells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World

Dec 21, 2024

Dec 05, 2024

HC Wainwright Issues Pessimistic Estimate for KZR Earnings - Defense World

Dec 05, 2024

Dec 04, 2024

Q4 EPS Estimate for Kezar Life Sciences Decreased by Analyst - MarketBeat

Dec 04, 2024

Dec 03, 2024

Kezar Life Sciences updates shareholder rights agreement - Investing.com

Dec 03, 2024

Dec 03, 2024

Kezar Life Sciences (NASDAQ:KZR) Given “Neutral” Rating at HC Wainwright - Defense World

Dec 03, 2024

Nov 18, 2024

William Blair Has Strong Estimate for KZR FY2024 Earnings - MarketBeat

Nov 18, 2024

Nov 18, 2024

FY2024 Earnings Estimate for KZR Issued By William Blair - Defense World

Nov 18, 2024

Nov 18, 2024

Kezar Life Sciences (NASDAQ:KZR) and Summit Therapeutics (NASDAQ:SMMT) Head-To-Head Contrast - Defense World

Nov 18, 2024

Nov 16, 2024

Wells Fargo & Company Has Lowered Expectations for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World

Nov 16, 2024

Nov 13, 2024

Kezar struck again with second FDA hold - Clinical Trials Arena

Nov 13, 2024

Nov 13, 2024

Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

Nov 13, 2024

Kezar Life Sciences (NASDAQ:KZR) Receives "Market Perform" Rating from William Blair - MarketBeat

Nov 13, 2024

Nov 12, 2024

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire

Nov 12, 2024

Nov 12, 2024

Kezar Life Sciences Reports $20.3M Q3 Loss, Halts Key Lupus Trial Amid Safety Concerns - StockTitan

Nov 12, 2024

Nov 05, 2024

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire

Nov 05, 2024

Oct 30, 2024

Kezar Life Sciences stock hits 52-week high at $7.5 By Investing.com - Investing.com South Africa

Oct 30, 2024

Oct 30, 2024

Kezar Life Sciences (NASDAQ:KZR) Shares Gap DownHere's What Happened - MarketBeat

Oct 30, 2024

Oct 30, 2024

Kezar Life Sciences announces 1-for-10 reverse stock split - MSN

Oct 30, 2024

Oct 30, 2024

Kezar Life Sciences stock hits 52-week high at $7.5 - Investing.com

Oct 30, 2024

Oct 29, 2024

Kezar Life Sciences announces 1-for-10 reverse stock split By Investing.com - Investing.com Canada

Oct 29, 2024

Oct 28, 2024

Kezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR) - MarketBeat

Oct 28, 2024

Oct 28, 2024

Kezar Life Sciences to Implement 1-for-10 Reverse Stock Split - Marketscreener.com

Oct 28, 2024

Oct 28, 2024

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - BioSpace

Oct 28, 2024

Oct 28, 2024

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split | KZR Stock News - StockTitan

Oct 28, 2024

Oct 27, 2024

What Makes Kezar Life Sciences (KZR) a New Buy Stock - MSN

Oct 27, 2024

Oct 18, 2024

Kezar shares unchanged as takeover bid rejected By Investing.com - Investing.com UK

Oct 18, 2024

Oct 18, 2024

Kezar Life Sciences discontinues lupus nephritis programme after fatalities - Clinical Trials Arena

Oct 18, 2024

Oct 18, 2024

Kezar rejects Concentra's acquisition offer, adopts rights plan By Investing.com - Investing.com South Africa

Oct 18, 2024

Oct 17, 2024

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - BioSpace

Oct 17, 2024

Oct 17, 2024

Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study - Benzinga

Oct 17, 2024

Oct 17, 2024

Concentra Biosciences, LLC cancelled the acquisition of Kezar Life Sciences, Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others. - Marketscreener.com

Oct 17, 2024

Oct 17, 2024

Kezar stock falls 11% after board rejects Concentra offer (NASDAQ:KZR) - Seeking Alpha

Oct 17, 2024

Oct 17, 2024

Kezar discontinues development of zetomipzomib for lupus nephritis (NASDAQ:KZR) - Seeking Alpha

Oct 17, 2024

Oct 17, 2024

Kezar stock falls 11% after board rejects Concentra offer (update) - MSN

Oct 17, 2024

Oct 17, 2024

Kezar to discontinue mid-stage trial for lupus treatment - Reuters

Oct 17, 2024

Oct 17, 2024

Kezar rejects Concentra's acquisition offer, adopts rights plan - Investing.com

Oct 17, 2024

Oct 17, 2024

Kezar to focus on AIH drug after halting lupus trial - Investing.com

Oct 17, 2024

Oct 17, 2024

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - StockTitan

Oct 17, 2024

Oct 15, 2024

Short Interest in Kezar Life Sciences, Inc. (NASDAQ:KZR) Increases By 13.6% - MarketBeat

Oct 15, 2024

Oct 15, 2024

Kezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Growth in Short Interest - Defense World

Oct 15, 2024

Oct 14, 2024

Kezar Life Sciences (NASDAQ:KZR) Given "Neutral" Rating at HC Wainwright - MarketBeat

Oct 14, 2024

Oct 14, 2024

H.C. Wainwright maintains Neutral rating on Kezar shares amid acquisition bid - Investing.com UK

Oct 14, 2024

Oct 11, 2024

Concentra Biosciences proposes to buy Kezar Life Sciences - Investing.com India

Oct 11, 2024

Oct 11, 2024

Concentra Biosciences proposes to buy Kezar Life Sciences By Investing.com - Investing.com Australia

Oct 11, 2024

Oct 10, 2024

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal - BioSpace

Oct 10, 2024